Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

remternetug

- PMLiVE

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

The real-world findings support the long-term benefits of continuous treatment

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

- PMLiVE

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease

Planning is currently underway for a placebo-controlled trial of the candidate

- PMLiVE

Roche to advance Parkinson’s disease candidate into phase 3 development

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

Sanofi gains access to Alzheimer’s candidate through $470m Vigil acquisition

A phase 2 trial of the drug is expected to launch in the third quarter of this year

- PMLiVE

FDA approves Fujirebio’s Lumipulse as first Alzheimer’s disease blood test

The device offers a less invasive option compared to current PET scans and CSF tests

- PMLiVE

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

International Alzheimer’s disease prevention trial in at-risk young adults begins

The study will evaluate whether the amyloid beta protein can be blocked from ever accumulating in the brain

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links